Clinical Trial News and Research

RSS

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.

22 May 2012

Polarization Gating Spectroscopy may detect pancreatic cancer

By simply shining a tiny light within the small intestine, close to that organ's junction with the pancreas, physicians at Mayo Clinic's campus in Florida have been able to detect pancreatic cancer 100 percent of the time in a small study.

22 May 2012

Data from EarlySense contact-free monitor clinical study presented at ATS conference

EarlySense, a market leader in proactive patient care solutions, announced today the results of a clinical study conducted at a Dignity Health Hospital. The data was presented today in a poster presentation titled: Effect Of Contactless Continuous Patient Monitoring In A Medical-Surgical Unit On Intensive Care Unit Transfers: A Controlled Clinical Trial at the ATS International Conference in San Francisco.

22 May 2012

Combination of vitamin D and BCG vaccine improves bladder cancer survival

The tuberculosis vaccine is often used as a treatment for bladder cancer, and adding vitamin D might improve the vaccine's effectiveness, according to new research from the University of Rochester Medical Center presented today at the American Urological Association annual meeting.

22 May 2012

Young children with cystic fibrosis do not benefit from concentrated saline therapy

Concentrated saline therapy not effective in young children with cystic fibrosis NIH-funded study demonstrates importance of conducting pediatric clinical trials.

21 May 2012

Growth promoting substance in human mesenchymal stem cells spurs restoration of nerves

A substance in human mesenchymal stem cells that promotes growth appears to spur restoration of nerves and their function in rodent models of multiple sclerosis (MS), researchers at Case Western Reserve University School of Medicine have found.

21 May 2012

Ipsen, Active Biotech complete half of planned recruitment in tasquinimod phase III study for CRPC

Active Biotech and Ipsen today announced that recruitment to the global, pivotal, randomized, double-blind, placebo-controlled phase III study of tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC) has reached an inclusion of 600 patients, half of the planned accrual.

21 May 2012

Receptos to present scientific podium presentation about RPC1063 at DDW 2012

Receptos Inc. today announced that company personnel will deliver a scientific podium presentation about RPC1063 at the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 at the San Diego Convention Center in San Diego, California. DDW attracts thousands of physicians, researchers, and academics from around the world to share the latest research in gastrointestinal health topics, for which DDW is the premier scientific conference.

19 May 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120.

19 May 2012

New study to find best way to give blood transfusions for severely injured patients

Researchers at The University of Texas Health Science Center at Houston (UTHealth) are launching a new research study to find the best way to give blood transfusions for severely injured patients predicted to require massive blood transfusions upon arrival to the Memorial Hermann-Texas Medical Center emergency department. Bryan Cotton, M.D., of UTHealth is principal investigator for this clinical study.

19 May 2012

Final results from C3BS-CQR-1 Phase II trial on heart failure

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22.

19 May 2012

Data from Almirall, Forest Labs’ aclidinium studies on COPD to be presented at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic Society (ATS) International Conference scheduled May 18 - 23 in San Francisco, CA.

19 May 2012

Biovest announces new data from BiovaxID Phase II mantle cell lymphoma trial

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that an abstract reporting new data from the BiovaxID Phase II mantle cell lymphoma clinical trial conducted by the U.S. National Cancer Institute (NCI) is now available on-line with the significance of these results to be presented by the NCI at the 2012 American Society of Clinical Oncology Annual Meeting.

19 May 2012

Ocera’s Zysa receives CE Mark to treat IBS-d

Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.

19 May 2012

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago.

19 May 2012

Childhood cancer research computing cluster to support precision medicine clinical trial

The childhood cancer research computing cluster created and donated by Dell for the Translational Genomics Research Institute (TGen) is ready to support the world's first precision medicine clinical trial for pediatric cancer.

19 May 2012

UK-led technologies set to transform treatments on the NHS

Video games, pioneering gene therapies and new medical devices are set to transform treatments on the NHS, with support from the Department of Health and the Wellcome Trust.

19 May 2012

Screening lung cancer tumor samples for genetic mutations can help tailor personalized treatment

Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas — the most common type of non-small cell lung cancer — and have developed drugs that can successfully address them, scientists have not yet identified targeted therapies for another type of non-small cell lung cancer known as squamous cell carcinoma.

19 May 2012

Sigmoid provides financial and product development update

Sigmoid Pharma Ltd., a privately-owned, specialty pharmaceutical and drug delivery company registered in Ireland, today provides an update on significant progress in 2011 and 2012.

19 May 2012

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two year period by the Cardioendocrine Research Group from the University of Otago in Christchurch, New Zealand and included patients admitted to Christchurch Hospital with acute decompensated heart failure.

18 May 2012

Clinical Trial News and Research

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

Polarization Gating Spectroscopy may detect pancreatic cancer

Data from EarlySense contact-free monitor clinical study presented at ATS conference

Combination of vitamin D and BCG vaccine improves bladder cancer survival

Young children with cystic fibrosis do not benefit from concentrated saline therapy

Growth promoting substance in human mesenchymal stem cells spurs restoration of nerves

Ipsen, Active Biotech complete half of planned recruitment in tasquinimod phase III study for CRPC

Receptos to present scientific podium presentation about RPC1063 at DDW 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

New study to find best way to give blood transfusions for severely injured patients

Final results from C3BS-CQR-1 Phase II trial on heart failure

Data from Almirall, Forest Labs’ aclidinium studies on COPD to be presented at ATS conference

Biovest announces new data from BiovaxID Phase II mantle cell lymphoma trial

Ocera’s Zysa receives CE Mark to treat IBS-d

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Childhood cancer research computing cluster to support precision medicine clinical trial

UK-led technologies set to transform treatments on the NHS

Screening lung cancer tumor samples for genetic mutations can help tailor personalized treatment

Sigmoid provides financial and product development update

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer